阴道镜检查时机与宫颈癌风险
该纵向分析纳入美国三个医疗系统21-79岁宫颈癌筛查结果异常患者17541例,比较阴道镜检查时机与后续宫颈癌风险。结果显示,3个月内与3-12个月内接受阴道镜者的宫颈癌风险无差异,而12个月内未行阴道镜者后续宫颈癌风险更高。
要点
- 3个月内与3-12个月内行阴道镜者,异常结果1年以上检出宫颈癌风险无差异(HR 1.07)。
- 12个月内未行阴道镜者,后续宫颈癌风险高于3个月内行阴道镜者(HR 2.34)。
- 高级别细胞学患者中,12个月内未行阴道镜者宫颈癌风险为12个月内行阴道镜者的3.12倍。
核心结论
- 异常结果后3个月内与3-12个月内行阴道镜者,1年以上宫颈癌风险无差异;12个月内未行阴道镜者后续宫颈癌风险更高。
研究设计与样本
- 纵向分析纳入美国德克萨斯州、马萨诸塞州和华盛顿州医疗系统中21-79岁宫颈癌检测结果异常患者17541例。
- 主要分析比较3个月内(≤91天)与3-12个月(92-365天)及12个月内未行阴道镜者,事后分析比较12个月内(≤365天)与12个月内未行阴道镜者。
- 采用多变量Cox比例风险回归控制年龄、风险状态、结果严重程度和医疗系统。
主要发现
- 17541例患者中,53.3%在3个月内行阴道镜,22.2%在3-12个月内行阴道镜,24.6%在12个月内未行阴道镜。
- 147例在12个月内诊断宫颈癌并被排除后续分析;65例(0.4%)在异常Pap或HPV检测结果后1年以上(≥366天)诊断宫颈癌。
- 与3个月内行阴道镜者相比,3-12个月内行阴道镜者1年以上检出宫颈癌风险无差异(HR 1.07,95%CI 0.54-2.12),12个月内未行阴道镜者风险更高(HR 2.34,95%CI 1.33-4.14)。
- 事后分析显示,12个月内未行阴道镜者宫颈癌诊断风险为12个月内行阴道镜者的2.29倍(95%CI 1.37-3.83)。
- 高级别细胞学结果患者中,12个月内未行阴道镜者宫颈癌检出风险为12个月内行阴道镜者的3.12倍(95%CI 1.47-6.70)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To quantify the association between time to colposcopy and risk of subsequent cervical cancer. METHODS: A longitudinal analysis of patients aged 21-79 years with an abnormal cervical cancer test result from health care systems in Texas, Massachusetts, and Washington was performed. The outcome was a cervical cancer diagnosis 12 months or more after the abnormal result. The primary analysis compared receipt of colposcopy within 3 months (91 days or less) with receipt of colposcopy at 3-12 months (92-365 days) and no colposcopy within 12 months of the abnormal test result; post hoc analyses compared colposcopy within 12 months (365 days or less) with no colposcopy within 12 months. Associations were assessed with multivariable Cox proportional hazards regression controlling for age, risk status, result severity, and health care system. RESULTS: Of 17,541 patients, 53.3% of patients received colposcopy within 3 months, 22.2% received colposcopy in 3-12 months, and 24.6% had no colposcopy within 12 months. One hundred forty-seven patients were diagnosed with cervical cancer within 12 months and removed from subsequent analyses. Sixty-five patients (0.4%) were diagnosed with cervical cancer more than 1 year (366 days or more) after the abnormal Pap or human papillomavirus test result. The risk of cervical cancer detection more than 1 year after the abnormal test result was not different in patients who received colposcopy within 3-12 months (hazard ratio [HR] 1.07, 95% CI 0.54-2.12) and higher among patients with no colposcopy within 12 months (HR 2.34, 95% CI 1.33-4.14) compared with patients who had colposcopy within 3 months. Post hoc analyses showed that the risk of cervical cancer diagnosis was 2.29-fold higher among those without colposcopy within 12 months compared with those who received colposcopy within 12 months (95% CI 1.37-3.83); among patients with high-grade cytology results, the risk of cervical cancer detection among those without colposcopy within 12 months was 3.12-fold higher compared with those who received colposcopy within 12 months (95% CI 1.47-6.70). CONCLUSION: There was no difference in cervical cancer risk at more than 1 year between patients who received colposcopy within 3 months compared with those who received colposcopy within 3-12 months of an abnormal result. Patients who did not receive colposcopy within 12 months of an abnormal result had a higher risk of subsequent cervical cancer compared with those who received a colposcopy within 12 months.
引用
- Alimena S, Lykken JM, Tiro JA, et al. Timing of Colposcopy and Risk of Cervical Cancer. Obstet Gynecol. 2023. PMID: 37607530. doi:10.1097/AOG.0000000000005313
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。